Compare XHR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XHR | TNDM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2013 |
| Metric | XHR | TNDM |
|---|---|---|
| Price | $14.91 | $21.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $14.14 | ★ $24.06 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 02-24-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | ★ 139.32 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,074,772,000.00 | $1,007,001,000.00 |
| Revenue This Year | $4.52 | $8.59 |
| Revenue Next Year | $3.04 | $10.19 |
| P/E Ratio | $27.00 | ★ N/A |
| Revenue Growth | 4.29 | ★ 17.87 |
| 52 Week Low | $8.55 | $9.98 |
| 52 Week High | $15.47 | $37.93 |
| Indicator | XHR | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 47.90 |
| Support Level | $13.92 | $21.35 |
| Resistance Level | $14.81 | $23.95 |
| Average True Range (ATR) | 0.35 | 1.04 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 71.48 | 27.15 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other. Xenia's revenue is divided between room, food and beverage, and other. The firm's customer groups include transient business, group business, and contract business.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.